Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Tirzepatide Tirzepatide (Mounjaro, Zepbound) is a newer medication that targets both GLP-1 and GIP receptors
Clinical trials have demonstrated substantial glycemic control improvements and weight loss averaging 15-21% of body weight at higher doses
Drug class: GIP/GLP-1/Glucagon receptor triagonist Route: Once-weekly subcutaneous injection Developer: Eli Lilly and Company Phase: Phase 3 (TRIUMPH program) Status: Investigational NOT TEY approved by FDA or EMA (despite what your online dealer told you ) Here's how it compares to the drugs most people already know: - Semaglutide (Ozempic/Wegovy): activates 1 receptor GLP-1 - Tirzepatide (Mounjaro/Zepbound): activates 2 receptors GLP-1 + GIP - Retatrutide: activates 3 receptors GLP-1 + GIP + Glucagon That third receptor the glucagon receptor is the differentiator
Clustering resulted in a clear separation of the endocrine and the exocrine cells (Supplemental Figure 3, B and C)
US$ 26.45
US$ 28.29
US$ 24.39
US$ 21.62
US$ 25.94
US$ 26.29
US$ 24.96
